Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human LRP4 Protein, C-His

Catalog #:   AHB08601 Specific References (50) DATASHEET
Applications: Bioactivity, ELISA, Immunogen, SDS-PAGE, WB
Expression system: Mammalian cells
Accession: O75096
Protein length: Ser21-Ser1725
Overview

Catalog No.

AHB08601

Expression system

Mammalian cells

Species

Homo sapiens (Human)

Protein length

Ser21-Ser1725

Predicted molecular weight

191 kDa

Nature

Recombinant

Endotoxin level

<0.1 EU/μg of the protein by the LAL method.

Purity

>90% as determined by SDS-PAGE.

Accession

O75096

Applications

Bioactivity, ELISA, Immunogen, SDS-PAGE, WB

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 2% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Low-density lipoprotein receptor-related protein 4, MEGF7, LRP10, LRP4, LRP-4, KIAA0816, Multiple epidermal growth factor-like domains 7

Data Image
  • SDS-PAGE
    SDS-PAGE for Recombinant Human LRP4 Protein
References

Potential therapeutic targets for deep vein thrombosis: A proteome-wide Mendelian randomization study., PMID:40462713

Periplocin targets LRP4 to regulate metabolic homeostasis and anti-inflammation for the treatment of IVDD., PMID:40440911

Alterations in gene expression associated with invasion of RAS-mutant thyroid tumors and their potential diagnostic and therapeutic utility., PMID:40440326

Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review., PMID:40356916

Agrin/Dok-7-induced JPH2 phosphorylation in muscle cells is involved in AChR clustering., PMID:40290048

Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects., PMID:40277145

Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience., PMID:40128464

A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder?, PMID:40062097

Single-nuclei sequencing of skeletal muscle reveals subsynaptic-specific transcripts involved in neuromuscular junction maintenance., PMID:40044687

LRP4 and Agrin Are Modulated by Cartilage Degeneration and Involved in β-Catenin Signaling in Human Articular Chondrocytes., PMID:39940775

(2R, 6R)-hydroxynorketamine alleviates postictal depression induced by pilocarpine through modulating LRP4 expression in hippocampal astrocytes., PMID:39923723

Identifying rare variants in genes related to bone phenotypes in a cohort of postmenopausal women., PMID:39915337

MuSK Regulates Neuromuscular Junction Nav1.4 Localization and Excitability., PMID:39880682

A bioinformatic approach to characterize the vitellogenin receptor and the low density lipoprotein receptor superfamily in the newt Cynops orientalis., PMID:39870874

Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial., PMID:39862880

Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study., PMID:39862879

Oleandrin inhibits osteoclast differentiation by targeting the LRP4/MAPK/NF-κB signalling pathway to treat osteoporosis., PMID:39823799

LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma., PMID:39723987

A clinical perspective on muscle specific kinase antibody positive myasthenia gravis., PMID:39703505

Regulation of miR-206 in denervated and dystrophic muscles, and its effect on acetylcholine receptor clustering., PMID:39575567

Heavy duty., PMID:39521071

Acute high-intensity muscle contraction moderates AChR gene expression independent of rapamycin-sensitive mTORC1 pathway in rat skeletal muscle., PMID:39501426

Mapping the sclerostin-LRP4 binding interface identifies critical interaction hotspots in loops 1 and 3 of sclerostin., PMID:39443289

Identification of potential biomarkers of papillary thyroid carcinoma., PMID:39400774

Lipoprotein Receptor-Related Protein 4 Antibody Positivity in the Youngest Patient in the Caucasus Region: A Case Report., PMID:39385918

The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments., PMID:39357636

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis., PMID:39288173

Myasthenia gravis., PMID:39174248

A class of chemical compounds enhances clustering of muscle nicotinic acetylcholine receptor in cultured myogenic cells., PMID:39024975

A conserved RNA switch for acetylcholine receptor clustering at neuromuscular junctions in chordates., PMID:39005407

Therapeutic challenges and unmet needs in the management of myasthenia gravis: an Italian expert opinion., PMID:38967883

Heterogeneous Presentations and Serologies in Myasthenia Gravis Patients Presenting with Dysphagia., PMID:38949061

[Effects of different exercise modes on neuromuscular junction and metabolism of skeletal muscle-related proteins in aging rats]., PMID:38939932

Unusual Presentation of Double-seronegative Myasthenia Gravis with Positive Anti-LRP4 Antibody: Diagnostic Utility of a Videofluoroscopic Swallowing Study., PMID:38897960

Identification of pleiotropic and specific therapeutic targets for cardio-cerebral diseases: A large-scale proteome-wide mendelian randomization and colocalization study., PMID:38820305

Effects of physical exercise on neuromuscular junction degeneration during ageing: A systematic review., PMID:38817243

Treating myasthenia gravis beyond the eye clinic., PMID:38789789

Agrin-Lrp4 pathway in hippocampal astrocytes restrains development of temporal lobe epilepsy through adenosine signaling., PMID:38783336

Neuronal LRP4 directs the development, maturation and cytoskeletal organization of Drosophila peripheral synapses., PMID:38738619

The MuSK agonist antibody protects the neuromuscular junction and extends the lifespan in C9orf72-ALS mice., PMID:38734896

Building, Breaking, and Repairing Neuromuscular Synapses., PMID:38697654

Suppression of AGRN enhances CD8+ T cell recruitment and inhibits breast cancer progression., PMID:38568853

Functional Signature of LRP4 Antibodies in Myasthenia Gravis., PMID:38507656

Myasthenia gravis-Pathophysiology, diagnosis, and treatment., PMID:38494283

Triple-seronegative myasthenia gravis: clinical and epidemiological characteristics., PMID:38316426

Antibody Response to HERV-K and HERV-W Envelope Epitopes in Patients with Myasthenia Gravis., PMID:38203616

GDF-10 Induces an Inhibitory Effect on Epithelial-Mesenchymal Transition of Laryngeal Cancer via LPR4., PMID:38163971

LRP4 site-specific variants in the third β-propeller domain causes congenital myasthenic syndrome type 17., PMID:38101565

LRP4-related signalling pathways and their regulatory role in neurological diseases., PMID:38065285

An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling., PMID:38051321

Datasheet
$ 460
Product specifications
50 μg 460 100 μg 690

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human LRP4 Protein, C-His [AHB08601]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only